There is a small but significant risk of developing congestive heart failure (CHF) among patients with multiple sclerosis (MS) who are receiving mitoxantrone (Novantrone), according to a report in the September 24th issue of Neurology.
“We undertook this study because the risk of cardiac toxicity after single-agent mitoxantrone therapy for MS has not been rigorously examined,” Dr. Donald E. Goodkin, from Amgen Corp., and colleagues reported.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!